Amneal Pharmaceuticals (NASDAQ:AMRX) Shareholder Returns Have Been Strong, Earning 132% in 1 Year
Amneal Pharmaceuticals (NASDAQ:AMRX) Shareholder Returns Have Been Strong, Earning 132% in 1 Year
Unfortunately, investing is risky - companies can and do go bankrupt. On the other hand, if you find a high quality business to buy (at the right price) you can more than double your money! Take, for example Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX). Its share price is already up an impressive 132% in the last twelve months. On top of that, the share price is up 33% in about a quarter. However, the stock hasn't done so well in the longer term, with the stock only up 2.8% in three years.
不幸的是,投資是有風險的——公司可以而且確實會破產。另一方面,如果你找到一家高質量的企業來收購(價格合適),你的錢可以翻一番以上!以Amneal Pharmicals, Inc.(納斯達克股票代碼:AMRX)爲例。在過去的十二個月中,其股價已經上漲了令人印象深刻的132%。最重要的是,股價在大約一個季度內上漲了33%。但是,從長遠來看,該股表現不佳,該股在三年內僅上漲了2.8%。
Since it's been a strong week for Amneal Pharmaceuticals shareholders, let's have a look at trend of the longer term fundamentals.
由於對Amneal Pharmicals的股東來說,這是強勁的一週,讓我們來看看長期基本面的趨勢。
To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
引用巴菲特的話說:“船隻將在世界各地航行,但Flat Earth Society將蓬勃發展。市場上的價格和價值之間將繼續存在巨大差異...”通過比較每股收益(EPS)和一段時間內的股價變化,我們可以了解投資者對公司的態度是如何隨着時間的推移而變化的。
Amneal Pharmaceuticals went from making a loss to reporting a profit, in the last year.
去年,Amneal Pharmicals從虧損變成了盈利。
We think the growth looks very prospective, so we're not surprised the market liked it too. Generally speaking the profitability inflection point is a great time to research a company closely, lest you miss an opportunity to profit.
我們認爲增長看起來很有前景,因此市場也喜歡增長並不奇怪。一般來說,盈利能力的轉折點是仔細研究公司的好時機,以免錯過獲利的機會。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
該公司的每股收益(隨着時間的推移)如下圖所示(點擊查看確切數字)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240215/0-b3c4d1e761f66306f568d07f6d899901-0-dbe0a533732c4ac1870e1f443a42cce7.png/big)
We know that Amneal Pharmaceuticals has improved its bottom line lately, but is it going to grow revenue? You could check out this free report showing analyst revenue forecasts.
我們知道Amneal Pharmicals最近提高了利潤,但它會增加收入嗎?您可以查看這份顯示分析師收入預測的免費報告。
A Different Perspective
不同的視角
It's good to see that Amneal Pharmaceuticals has rewarded shareholders with a total shareholder return of 132% in the last twelve months. That certainly beats the loss of about 9% per year over the last half decade. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 2 warning signs for Amneal Pharmaceuticals (1 can't be ignored) that you should be aware of.
很高興看到Amneal Pharmicals在過去十二個月中向股東提供了132%的總股東回報率。這無疑超過了過去五年中每年約9%的損失。長期虧損使我們保持謹慎,但短期股東總回報率的增長無疑暗示着更光明的未來。我發現將長期股價視爲業務績效的代表非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,我們已經確定了Amneal Pharmicals的兩個警告信號(其中一個不容忽視),你應該注意這些信號。
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).
如果你想與管理層一起購買股票,那麼你可能會喜歡這份免費的公司名單。(提示:業內人士一直在購買它們)。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。